Partnering opens in:
- 00Days
- 00Hrs
- 00Mins
- 00Secs
Day 1 2023 - *Subject to change* - CET/CEST (Cent Europe Summer, GMT+2)
Day 1 2023 - *Subject to change* - CET/CEST (Cent Europe Summer, GMT+2)
- Anna Chrisman - Managing Director, EBD & Life Science, Informa Connect
- Ralf Huss - Managing Director, BioM Biotech Cluster Development GmbH
- Daniel Chancellor - Thought Leadership and Consulting Director, Citeline
- Isma Hachi - Director, IQVIA
- Alexendra Zemp - Partner, McKinsey & Company
- Simon Turner - Partner, Sofinnova Partners
- Thomas Clozel - Chief Executive Officer and Co-founder, OWKIN
Auding the strength of pharma pipelines and identifying partnering opportunities
- Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate
- Nisha Nanda - Group Vice President, Business Development, Eli Lilly and Company
- John Copeland - Head of MSD International Commercial Business Development & Transactions, MSD
- David Jenkins - Vice President, Head of External Innovation, Ipsen
In conversation with market leading pharmaceutical companies, this session uncovers the latest trends, and market size of the therapeutic area. The discussion will also highlight the story behind the discovery (and commercialization) of the novel drugs and why the therapy is thriving in uncertain times, creating further opportunity in the industry.
- Melanie Senior - Senior Writer & Analyst, Nature Portfolio
- Axel Haupt - Early Clinical Investigation for Diabetes & Obesity and Complications, Eli Lilly and Company
- Laura Lane - Vice President - Venture Sciences (Europe Head), Eli Lilly and Company
The recent spotlight on the use of AI in the life sciences has led to questions around the potential and ‘readiness’ of the technology. This session dives into the acquisition of AI startups and focuses on use cases on how pharma (and biotech) companies use AI for drug discovery and development, for critical diseases. It also aims to discuss the regulatory perspective of AI, AI safety and the potential of AI in the future.
Love it or hate it - The European Pharmaceutical Legislation is going to redefine the business model of biotechnology in Europe. This panel will discuss what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.
Join the German Orchestra who demonstrate how poor and positive leadership, along with weak and strong communication, impacts the performance of a team. Understand the importance of the supportive team and find out if being either a hierarchical, old-school or empathic leader is the secret to success is this new era of the life sciences.